Bioventus Inc (BVS)vsEdwards Lifesciences Corp (EW)
BVS
Bioventus Inc
$9.04
+3.91%
HEALTHCARE · Cap: $589.41M
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 994% more annual revenue ($6.30B vs $576.30M). EW leads profitability with a 17.4% profit margin vs 4.9%. BVS appears more attractively valued with a PEG of 1.12. EW earns a higher WallStSmart Score of 61/100 (C+).
BVS
Buy51
out of 100
Grade: C-
EW
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BVS.
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
4.9% margin — thin
Elevated debt levels
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : BVS
PEG of 1.12 suggests the stock is reasonably priced for its growth.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : BVS
The primary concerns for BVS are EPS Growth, Market Cap, Profit Margin. Thin 4.9% margins leave little buffer for downturns.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Key Dynamics to Monitor
BVS profiles as a value stock while EW is a growth play — different risk/reward profiles.
EW carries more volatility with a beta of 0.87 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
BVS generates stronger free cash flow (8M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 51/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bioventus Inc
HEALTHCARE · MEDICAL DEVICES · USA
Bioventus Inc., a medical device company, focuses on developing and commercializing clinical treatments that involve and enhance the body's natural healing process in the United States and internationally. The company is headquartered in Durham, North Carolina.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?